FOCR offers path for validating ctDNA as an early endpoint for drug approval
Regulatory NewsMary Ellen Schneider
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsDiagnostics/IVDsNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsMary Ellen SchneiderBiologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsDiagnostics/IVDsNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy